EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc., a biopharmaceutical company specializing in exosome-based therapies, will be presenting its innovative spinal cord injury treatment at the Exosomes Europe conference in London. CEO Dr. Lior Shaltiel will discuss the company’s ExoPTEN nanodrug, which has shown promising results in recovering motor function in preclinical trials and has received Orphan Drug Designation by the FDA. The conference is a convergence of industry and academic leaders aimed at advancing exosome products from clinical stages to market.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
